• About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • iNKT Cells
    • ARDS & Infectious Diseases
    • Cancer
    • GvHD
  • Publications
    • Presentations & Manuscripts
    • In The News
  • Platform
    • Manufacturing
    • Engineering
  • Pipeline
  • Investor & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Financials & Filings
    • Corporate Governance
  • Careers
  • Contact

Massachusetts company MiNK Therapeutics working to make chemotherapy a thing of the past

Posted on June 22, 2023 by Dana Rodriguez - CBS

  • You are currently browsing the archives for the CBS category.

  • Pages

    • agenT-797, a native allogeneic “off-the-shelf’ iNKT cell therapy product shows anti-tumor activity
    • ARDS & Infectious Diseases
    • Cancer
    • Careers
    • Contact
    • Engineering
    • Front-page
    • GvHD
    • Homepage
    • Identification and characterization of an allogeneic iNKT-CAR Targeting BCMA
    • In The News
    • iNKT Cells
    • Manufacturing
    • MiNK Nasdaq ceremony
    • MiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC
    • Our Science
    • Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-based cell therapy drug product
    • Pipeline
    • Platform
    • Press Releases
    • Privacy Policy
    • Publications
    • Terms and Conditions

  • Archives

    • June 2023

  • Categories

    • 7 News (1)
    • Twitter Broadcast with TradeTalks (1)
    • Nasdaq (1)
    • CGTlive (4)
    • Jen – Ted Talk (1)
    • Personalized Medicines Podcast (1)
    • LifeScience Leader (1)
    • EndPoint News (1)
    • CBS (1)
MiNK

MiNK Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010

Phone: 212.994.8250

Email: webmaster@minktherapeutics.com

Terms and Conditions Privacy Policy Cookie Policy © Copyright 2023. All Rights Reserved.